The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Shares of Verve Therapeutics skyrocketed 75% Tuesday morning after Eli Lilly announced that it would acquire the gene-editing ...

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...

Deal would add a potential treatment for cardiovascular disease to Eli Lilly’s portfolio.

Beyond current successes, Eli Lilly is innovating with a potential game-changing oral GLP-1, orforglipron. Read why I ...

Boston-based Verve is a rare example of a gene-editing company targeting a disease that affects a large population, offering ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $943.0, a high ...

Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for ...

Eli Lilly is the most likely healthcare stock to reach a $1 trillion valuation, and I believe it could hit that plateau by 2027. Image source: Getty Images. A big catalyst could be coming soon.

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and the risks. Click for my LLY stock update.

Eli Lilly’s big moment is being powered by two superstar drugs: Mounjaro and Zepbound. Mounjaro , a treatment for type 2 diabetes, brought in $3.84 billion last quarter, a whopping 113% increase ...

The head of drugmaker Eli Lilly, which sells the popular weight-loss drug Zepbound, urged the Trump administration to ease up on its tariff rollout because it could hurt Lilly’s business and the ...